Liao, L., Zhang, H
In D-galactose-induced aging mice, oral administration of the product significantly increased NAD+ levels in liver and adipose tissue, activated mitochondrial energy metabolism pathways, improved insulin sensitivity, lowered blood glucose and lipid levels, reduced visceral fat accumulation, and increased energy expenditure, alleviating fatigue and abnormal body weight associated with aging
Articles and biomarkers were classified into more than one category and/or country when applicable
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
For people whose sleep apnea is severe enough to affect daily functioning, the greater weight loss from tirzepatide or potentially retatrutide could be a deciding factor in medication choice
.png)
